• Researchers In Japan Identify High-Potential Biomarker Of Gastric Cancer

    Dec 05 | Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more. More

  • Follow the Money: Sepsis Diagnostic Test, Expanding Cardiovascular Disease Info, Oncology, Peptide Therapeutics, CRISPR

    Nov 30 | Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more. More

  • Illumina Partners With Veracyte; Boston Scientific Corporation Acquires Relievant Medsystems; Oxford Nanopore Collaborates With Fabric Genomics

    Nov 29 | Diagnostics World | Illumina enters a multi-year agreement with Veracyte to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument; Boston Scientific Corporation acquires Relievant Medsystems to add to chronic pain portfolio; Oxford Nanopore Technologies and Fabric Genomics collaborate to develop a software solution analysis and clinical reporting of rich genomic data for faster insights to support rapid disease characterization of babies and children with genetic disorders in acute settings; more. More

  • AI-Based Platform For Detecting AFib Put To The Test In VA Facilities

    Nov 28 | Diagnostics World | Investigators at Cedars-Sinai Medical Center are looking to minimize the biases in the data used by artificial intelligence (AI) algorithms, most recently a deep learning model trained on nearly a million electrocardiograms (ECGs) to identify people with abnormal heart rhythms. More

  • For Equitable CF Screening, We Should Expand Our Definition of Pathogenic Variants

    Nov 21 | Diagnostics World | Cystic fibrosis (CF) is one of the few genetic disorders to be considered both serious and common enough to merit universal carrier or prenatal screening. Unfortunately, though, current testing approaches are caught between evolution and revolution even as they continue to produce suboptimal results for people of non-European ancestry. More

  • Illumina Releases Updated TruSight Oncology Liquid Biopsy Assay

    Nov 16 | Diagnostics World | Illumina announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing. More

  • The Last Mile In Preventing A Deadly Hospital Infection

    Nov 15 | Diagnostics World | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals. More

  • Illumina Launches Program to Discount Pathogen Sequencing Tools for Public Health

    Nov 13 | Bio-IT World | Illumina has launched the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs) and reduced prices. More

  • Prevention Strategy For Alzheimer’s Disease Now On The Horizon

    Nov 08 | Diagnostics World | It may be possible one day soon to prevent Alzheimer’s disease, a devastating illness currently suffered by more than 30 million people worldwide. The good news comes straight from the mouth of Randall J. Bateman, M.D., professor of neurology at Washington University School of Medicine and director of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit (DIAN-TU). More

  • Early Detection Of Alzheimer’s Disease From Blood A Near-Term Possibility

    Nov 07 | Diagnostics World | Mayo Clinic and Oxford Nanopore Technologies teams up in a multi-year joint development collaboration to help improve patient care, including some of the hardest-to-characterize conditions and sequencing DNA; Walgreens and the Cardiovascular Research Foundation (CRF) collaborates to drive the PREVUE-VALVE study, which will help pave the way for the development of new therapies and tools for VHD detection and diagnosis; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more. More
View more articles

 
DXX-Industry-spotlight

merck


Lateral Flow Assay Development Services

Discover our Assay Development Services for fast-access expert guidance and global lab support for your LFA development or optimization at any stage. Use our expertise to get over design hurdles big and small.

Learn more